Royalty Pharma (NASDAQ:RPRX) Stock: Insider Terrance Coyne Sells 232,536 Shares

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) CFO Terrance Coyne sold 232,536 shares of the firm’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $68.87, for a total value of $16,014,754.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Stock Down 0.0%

Shares of Royalty Pharma stock traded down $0.01 during trading on Wednesday, hitting $68.67. 3,192,451 shares of the stock traded hands, compared to its average volume of 3,426,408. The stock has a market cap of $39.39 billion, a P/E ratio of 57.23, a PEG ratio of 1.36 and a beta of 0.37. The company has a fifty day moving average price of $61.77 and a two-hundred day moving average price of $54.81. Royalty Pharma PLC has a twelve month low of $37.31 and a twelve month high of $70.37. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.29 and a current ratio of 1.29.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $0.2350 per share. This represents a $0.94 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma’s dividend payout ratio (DPR) is presently 78.33%.

Analysts Set New Price Targets

RPRX has been the subject of several recent research reports. Citigroup boosted their target price on shares of Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. JPMorgan Chase & Co. lifted their price objective on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of Royalty Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 11th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $65.00.

View Our Latest Report on Royalty Pharma

Institutional Investors Weigh In On Royalty Pharma

Large investors have recently added to or reduced their stakes in the stock. Coastal Bridge Advisors LLC bought a new position in shares of Royalty Pharma in the third quarter valued at approximately $329,000. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in shares of Royalty Pharma by 4.7% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 10,542 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 471 shares during the last quarter. Kentucky Retirement Systems lifted its stake in shares of Royalty Pharma by 7.3% in the third quarter. Kentucky Retirement Systems now owns 26,046 shares of the biopharmaceutical company’s stock worth $1,520,000 after buying an additional 1,777 shares during the last quarter. Regal Partners Ltd boosted its holdings in shares of Royalty Pharma by 2.9% during the 3rd quarter. Regal Partners Ltd now owns 2,519,922 shares of the biopharmaceutical company’s stock worth $147,063,000 after buying an additional 72,043 shares during the period. Finally, Allworth Financial LP boosted its holdings in shares of Royalty Pharma by 10.1% during the 3rd quarter. Allworth Financial LP now owns 8,212 shares of the biopharmaceutical company’s stock worth $479,000 after buying an additional 756 shares during the period. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Read More

Insider Buying and Selling by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.